AN2 Therapeutics Reports Preclinical Data for Chagas Candidate, Advancing to Phase 2

What happened

AN2 Therapeutics announced positive enabling data from two non-human primate studies of its oral CPSF3 inhibitor, AN2-502998, supporting advancement to a Phase 2 study for chronic Chagas disease. The data, while from animal models, showed activity that the company believes justifies moving into proof-of-concept human trials. This update comes later than the company's prior guidance for Phase 1 human data in Q1 2026, raising questions about the timing and quality of human results. The company plans to leverage its DNDi collaboration to initiate Phase 2, but the lack of disclosed human safety and pharmacokinetic data is a notable gap. Critical investors will view this as a pathway that bypasses standard Phase 1 human readouts, increasing execution risk despite the positive animal findings.

Implication

The shift to Phase 2 without full human Phase 1 results could compress timelines but also risks later-stage failure if human tolerability or efficacy differs materially from animal models. Investors should demand clarity on human data and watch for registry entries; a clean Phase 2 start with DNDi support could re-rate the stock, but any safety signal would be devastating given the thin cash runway.

Thesis delta

The original thesis built around a clean human Phase 1 data readout in Q1 2026; this news replaces that with preclinical data and a jump to Phase 2, shifting the risk profile from a human proof-of-concept to an animal-derived one. The lack of human safety data increases the chance of clinical headwinds, while the delayed timing relative to prior guidance suggests the company's execution may be less crisp than initially modeled.